title: Screening of complex fucoidans from four brown algae species as procoagulant agents.
abstract: Fucoidans are complex sulfated polysaccharides extracted from brown algae. Depending on the concentration, they have been shown to stimulate and inhibit blood coagulation in vitro. Promotion of coagulation is mediated by blocking tissue factor pathway inhibitor (TFPI). We screened fucoidan extracts from four brown algae species in vitro with respect to their potential to improve coagulation in bleeding disorders. The fucoidans' pro- and anticoagulant activities were assessed by global hemostatic and standard clotting assays. Results showed that fucoidans improved coagulation parameters. Some fucoidans also activated the contact pathway of coagulation, an undesired property reported for sulfated glycosaminoglycans. Chemical evaluation of fucoidans' complex and variable structure included molecular weight (Mw), polydispersity (polyD), structural heterogeneity, and organic and inorganic impurities. Herewith, we describe a screening strategy that facilitates the identification of crude fucoidan extracts with desired biological and structural properties for improvement of compromised coagulation like in hemophilia.
authors.affiliation: Baxter Healthcare Corporation, Round Lake, IL, USA; College of Pharmaceutical Sciences, Soochow University, Suzhou, China.
authors.forename: Zhenqing
authors.initials: Z
authors.lastname: Zhang
authors.affiliation: Baxter Innovations GmbH, Vienna, Austria. Electronic address: susanne_till@baxter.com.
authors.forename: Susanne
authors.initials: S
authors.lastname: Till
authors.affiliation: Baxter Innovations GmbH, Vienna, Austria.
authors.forename: Sabine
authors.initials: S
authors.lastname: Knappe
authors.affiliation: Baxter Healthcare Corporation, Round Lake, IL, USA.
authors.forename: Catherine
authors.initials: C
authors.lastname: Quinn
authors.affiliation: Baxter Healthcare Corporation, Round Lake, IL, USA.
authors.forename: James
authors.initials: J
authors.lastname: Catarello
authors.affiliation: Baxter Healthcare Corporation, Round Lake, IL, USA.
authors.forename: G Joseph
authors.initials: GJ
authors.lastname: Ray
authors.affiliation: Baxter Innovations GmbH, Vienna, Austria. Electronic address: fritz_scheiflinger@baxter.com.
authors.forename: Friedrich
authors.initials: F
authors.lastname: Scheiflinger
authors.affiliation: Baxter Healthcare Corporation, Round Lake, IL, USA.
authors.forename: Christina M
authors.initials: CM
authors.lastname: Szabo
authors.affiliation: Baxter Innovations GmbH, Vienna, Austria.
authors.forename: Michael
authors.initials: M
authors.lastname: Dockal
mesh_terms: D000464:Alginates / Q000032:analysis; D000925:Anticoagulants / Q000737:chemistry / Q000494:pharmacology*; D001777:Blood Coagulation / Q000187:drug effects*; D003029:Coagulants / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D008074:Lipoproteins / Q000037:antagonists & inhibitors; D009005:Monosaccharides / Q000032:analysis; D010314:Partial Thromboplastin Time; D000459:Phaeophyceae; D011134:Polysaccharides / Q000737:chemistry / Q000494:pharmacology*
chemical_list: D000464:Alginates; D000925:Anticoagulants; D003029:Coagulants; D008074:Lipoproteins; D009005:Monosaccharides; D011134:Polysaccharides; C051928:lipoprotein-associated coagulation inhibitor; C007789:fucoidan
keywords: Fucoidan; Hemophilia; Hemostasis; NMR; Screening; Structure